期刊文献+

Molecular features and expression of DAZAP2 in human multiple myeloma 被引量:2

Molecular features and expression of DAZAP2 in human multiple myeloma
原文传递
导出
摘要 Background In our previous study, we found that DAZAP2 was the most significantly down regulated gene when differential screening of complementary DNA (cDNA) chips were used to analyze mRNA isolated from bone marrow mononuclear cells from newly diagnosed multiple myeloma (MM) patients without anticancer treatment. In this study, we observed DAZAP2 mRNA and protein expression in the mononuclear cells from MM bone marrow and investigated its role in the pathogenesis of MM. Methods The full-length cDNA of DAZAP2 was cloned and sequenced from mononuclear cells from human bone marrow. The nucleotide and amino acid sequences of DAZAP2 were analyzed using the ClustalW program. A dendrogram was constructed by multiple sequence alignment using ClustalW and amino acid sequence identity/similarity was derived based on comparisons attained using the MegAlign software. The recombinant pEGFP expression vector was constructed and the confocal microscopy was used for the localization of the DAZAP2 protein in transfected COS7 cells. The expression of DAZAP2 mRNA was detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and the expression level of DAZAP2 protein was detected by Western blotting analysis in MM samples. Results DAZAP2 proteins of vertebrates is highly conserved in evolution. It contains a proline-rich region, several potential SH2 and SH3 domain-binding motifs and a possible protein kinase C (PKC) phosphorylation site. We showed by confocal microscopy that the DAZAP2 protein predominantly resides in the cytoplasm with a discrete pattern of punctuated distribution. The expression of DAZAP2 was not detected in 24 of 36 MM samples by semi-quantitative RT-PCR. In contrast, DAZAP2 expression was detected in all 30 normal controls. The expression level of DAZAP2 protein was assayed by Western blotting analysis, showing a robust down-regulation in MM patients (P〈0.001) that matched with the results of the RT-PCR. Conclusions DAZAP2 is downregulated in MM samples and it may be a signal molecule in MM cells. DAZAP2 is involved in the pathogenesis of MM and could be used as a genetic marker for MM. Background In our previous study, we found that DAZAP2 was the most significantly down regulated gene when differential screening of complementary DNA (cDNA) chips were used to analyze mRNA isolated from bone marrow mononuclear cells from newly diagnosed multiple myeloma (MM) patients without anticancer treatment. In this study, we observed DAZAP2 mRNA and protein expression in the mononuclear cells from MM bone marrow and investigated its role in the pathogenesis of MM. Methods The full-length cDNA of DAZAP2 was cloned and sequenced from mononuclear cells from human bone marrow. The nucleotide and amino acid sequences of DAZAP2 were analyzed using the ClustalW program. A dendrogram was constructed by multiple sequence alignment using ClustalW and amino acid sequence identity/similarity was derived based on comparisons attained using the MegAlign software. The recombinant pEGFP expression vector was constructed and the confocal microscopy was used for the localization of the DAZAP2 protein in transfected COS7 cells. The expression of DAZAP2 mRNA was detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and the expression level of DAZAP2 protein was detected by Western blotting analysis in MM samples. Results DAZAP2 proteins of vertebrates is highly conserved in evolution. It contains a proline-rich region, several potential SH2 and SH3 domain-binding motifs and a possible protein kinase C (PKC) phosphorylation site. We showed by confocal microscopy that the DAZAP2 protein predominantly resides in the cytoplasm with a discrete pattern of punctuated distribution. The expression of DAZAP2 was not detected in 24 of 36 MM samples by semi-quantitative RT-PCR. In contrast, DAZAP2 expression was detected in all 30 normal controls. The expression level of DAZAP2 protein was assayed by Western blotting analysis, showing a robust down-regulation in MM patients (P〈0.001) that matched with the results of the RT-PCR. Conclusions DAZAP2 is downregulated in MM samples and it may be a signal molecule in MM cells. DAZAP2 is involved in the pathogenesis of MM and could be used as a genetic marker for MM.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2007年第19期1659-1665,共7页 中华医学杂志(英文版)
基金 This work was supported by the grants from the National Natural Science Foundation of China(No.30270750, 30300406 and 30400529).
关键词 DAZAP2 gene structure gene expression multiple myeloma DAZAP2 gene structure gene expression multiple myeloma
  • 相关文献

参考文献2

二级参考文献18

  • 1王良绪编译.血液肿瘤学:第3版[M].沈阳:辽宁教育出版社,2000.407-540.
  • 2John DV, Guilhern C, Karin T,et al. Identifying intercellular signaling.genes expressed in malignant plasma cells by using complementary DNA arrays[J]. Blood ,2001,98:771-780.
  • 3Yata K, Sadahira Y, Otsuki T, et al. Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1 [ J]. Br J Haematol,2001 , 114:591-599.
  • 4Mazumder S, Gong B, Almasan A, et al. Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells [ J ]. Oncogene, 2000,19 : 2828 -2835.
  • 5Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors[J]. Blood,2001 ,98:3082-3086.
  • 6Avet-Loiseau H,Li JY,Godon C,et al. P53 deletion is not a frequent event in multiple myeloma [ J ]. Br J Haematol, 1999,106 :717-7i9.
  • 7Watts GS, Futscher BW, Isett R, et al. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis sigrraling pathways [ J ]. J Pharmacol Exp Ther,2001,299:434-441.
  • 8John S Jr, Erming T, Jeffrey S, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH[ J]. Blood ,2000,96 : 1505-1511.
  • 9Elenius K, Paul S, Allison G, et al. Activation of HER4 by hepa-rin-binding EGF-like growth factor stimulates chemotaxis but not proliferation [ J ]. EMBO J, 1997.16 : 1268-1278.
  • 10Costes V, Magen V, Legouffe E, et al. The Mil 5 monoclonal antibody(anti-syndecan-l) is a reliable marker for quantifying plasma cells in paraffin-embeded bone marrow biopsy specimens [ J ].Hum Pathol, 1999,30 : 1405-1411.

共引文献13

同被引文献46

  • 1YiwuShi,SaiqunLuo,JianbinPeng,ChenghanHuang,DarenTan,WeixinHu.The Structure, Expression, and Function Prediction of DAZAP2, A Down-Regulated Gene in Multiple Myeloma[J].Genomics, Proteomics & Bioinformatics,2004,2(1):47-54. 被引量:2
  • 2JAIR K W,BACHMAN K E,SUZUKI H,et al.De novo CpGisland methylation in human cancer cells[J].Cancer Research,2006,66(2):682-692.
  • 3PAZ M F,FRAGA M F,AVILA S,et al.A systematic profileof DNA methylation in human cancer cell lines[J].Cancer Re-search,2003,63(5):1114-1121.
  • 4YOO K H,PARK Y K,CHANG S G,et al.DNA hypomethy-lation of interleukin 8 in clear cell renal cell carcinoma[J].Oncology Letter,2013,5(1):39-42.
  • 5OZDEMIR F,ALTINISIK J,KARATEKE A,et al.Methylationof tumor suppressor genes in ovarian cancer[J].Experimentaland Therapeutic Medicine,2012,4(6):1092-1096.
  • 6HIBI K,SAKUREBA K,SHIRAHATA A,et al.Methylation ofthe UNC5C gene is frequently detected in hepatocellular car-cinoma[J].Hepato-gastroenterology,2012,59(120):2573-2575.
  • 7HIBI K,SAKATA M,YOKOMIZI K,et al.Methylation of theWNT5A gene is frequently detected in early gastric carcinoma[J].Hepato-gastroenterology,2012,59(120):2661-2663.
  • 8HELLETR G,SCHMIDT W M,ZEGLER B,et al.Genome-wide transcriptional response to 5-aza-2′-deoxycytidine andtrichostatin a in multiple myeloma cells[J].Cancer Research,2008,68(1):44-54.
  • 9WALKER B A,WARDELLL C P,CHIECCHIO L,et al.Aberrant global methylation patterns affect the molecularpathogenesis and prognosis of multiple myeloma[J].Blood,2011,117(2):553-562.
  • 10HURT E M,THOMAS S B,PENG B J,et al.Reversal of p53epigenetic silencing in multiple myeloma permits apoptosis bya p53 activato[J].Cancer Biology&Therapy,2006,5(9):1154-1160.

引证文献2

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部